Table 3.

Multivariable analysis of factors associated with a CDT of BMA in the overall population (N = 193)

Variable	Odds ratio	95% confidence interval	P value
First model
Hematological malignancy, cancer, or non-malignant hematological abnormality known on admission	3.70	[1.44–9.33]	0.007
Indication of BMA excluding isolated TPa,b	3.69	[1.46–9.30]	0.006
SOFA scorec	1.15	[1.04–1.28]	0.006
Pre-BMA HScorec,d	1.03	[1.02–1.04]	< 0.001
Second model
Hematological malignancy, cancer, or non-malignant hematological abnormality known on admission	3.21	[1.78–8.76]	0.023
Indication of BMA excluding isolated TPa,b	4.53	[1.66–12.38]	0.003
SOFA—platelet-count SOFA subscorec	1.15	[1.03–1.29]	0.013
Pre-BMA HScorec,d	1.03	[1.02–1.04]	< 0.001
Platelet count SOFA subscore 0 versus other groupsc	2.38	[0.76-7.50]	0.138

BMA bone marrow aspiration, CDT contribution to diagnosis and/or treatment, Hscore reactive hemophagocytic syndrome diagnostic score, SOFA sequential organ failure assessment, TP thrombocytopenia

^aThrombocytopenia may be present or absent in these patients

^bIsolated thrombocytopenia, i.e., thrombocytopenia was the only indication for BMA

^cPer point

^dCalculated with no points assigned for the cytological variable